Table 3 Competing risks regression for the association between RS and iLRR
| Treatment group | Competing risk regression for iLRR | 60-month cumulative incidence of iLRR (95% CI) | |
|---|---|---|---|
| HR (95% CI) | P | ||
| Entire cohort | |||
| RS < 25 | 1.0 (reference) | 1.8% (1.0–3.0%) | |
| RS ≥25 | 1.14 (0.39–3.36) | 0.81 | 3.2% (1.0–7.6%) |
| Hormonal therapy without chemotherapy | |||
| RS < 25 | 1.0 (reference) | 1.9% (1.0–3.3%) | |
| RS ≥25 | 3.66 (1.07–12.5) | 0.04 | 10.3% (2.2–25.7%) |